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Abstract
Background: Globally syphilis is an important yet preventable cause of stillbirth, neonatal mortality and morbidity.
Objectives: This review sought to estimate the effect of detection and treatment of active syphilis in pregnancy
with at least 2.4MU benzathine penicillin (or equivalent) on syphilis-related stillbirths and neonatal mortality.
Methods: We conducted a systematic literature review of multiple databases to identify relevant studies. Data
were abstracted into standardised tables and the quality of evidence was assessed using adapted GRADE criteria.
Where appropriate, meta-analyses were undertaken.
Results: Moderate quality evidence (3 studies) supports a reduction in the incidence of clinical congenital syphilis
of 97% (95% c.i 93 – 98%) with detection and treatment of women with active syphilis in pregnancy with at least
2.4MU penicillin. The results of meta-analyses suggest that treatment with penicillin is associated with an 82%
reduction in stillbirth (95% c.i. 67 – 90%) (8 studies), a 64% reduction in preterm delivery (95% c.i. 53 – 73%) (7
studies) and an 80% reduction in neonatal deaths (95% c.i. 68 – 87%) (5 studies). Although these effect estimates
were large and remarkably consistent across studies, few of the studies adjusted for potential confounding factors
and thus the overall quality of the evidence was considered low. However, given these large observed effects and
a clear biological mechanism for effectiveness the GRADE recommendation is strong.
Conclusion: Detection and appropriate, timely penicillin treatment is a highly effective intervention to reduce
adverse syphilis-related pregnancy outcomes. More research is required to identify the most cost-effective
strategies for achieving maximum coverage of screening for all pregnant women, and access to treatment if
required.
Background
Transmission of maternal syphilis infection to the foetus
during pregnancy has been described in the medical lit-
erature as long ago as 1497 and has been much studied
over the past 500 years [1]. However, despite the avail-
ability of diagnostic tests for a century and of cheap,
effective therapy for over 50 years, WHO currently esti-
mates between 730,000 and 1,500,000 adverse pregnancy
outcomes are caused by untreated maternal syphilis
each year, of which about 650,000 are foetal and new-
born deaths [2,3]. In many regions congenital syphilis
remains an important public health problem, e.g Latin
America and Africa [2], and the incidence is increasing
in some countries, for example China [4,5]. In 2007
WHO launched a programme for the global elimination
of congenital syphilis through strengthening existing
maternal and newborn health (MNCH) systems in
highly affected nations [6].
Pathophysiology
In 2001, twelve million people globally were estimated
to be infected with the causative agent of syphilis, the
spirochete Treponema pallidum (T.pallidum) [7]. Syphi-
lis classically presents in its primary stage with a pain-
less, spontaneously resolving ulcer (chancre), lasting 3 –
6 weeks, that typically occurs around 21 days, but which
may occur up to 3 months post infection. This is
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which consists of a more diffuse inflammatory response
characterised by an exanthema which manifests variably
and for which healthcare is often not sought even if
available. This stage also resolves spontaneously and is
followed by an asymptomatic ‘latent period’. Untreated,
15 – 40% of infected individuals develop late ‘tertiary’
complications that may occur years after the initial
infection: e.g. granulomas, neuropathic joint disease, car-
diovascular and neurological complications.
Diagnosis
Syphilis can be difficult to diagnose, since T pallidum
cannot be cultured in vitro,a n dP C R - b a s e dt e s t sa r e
unavailable outside research settings. While direct diag-
nosis of characteristic treponemes with darkfield micro-
scopy is highly sensitive and specific, this requires
exudate obtained from a lesion during the brief primary
stage. Thus most infections are identified using serologic
tests that support, rather than establish, a syphilis diag-
nosis. Serologic tests fall into 2 broad categories: non-
treponemal tests (e.g., RPR, VDRL) measure antibody to
a component of mammalian cell membranes modified
by Tp a l l i d u m . Positive RPR tests are reported as the
highest titre for which tests are still positive after dilu-
tion, with titre correlating with recentness of infection
and stage of disease and falling over time or with treat-
ment. In general, titres >1:4 have been considered to
represent “active” infections, more likely to be more
recently acquired and infectious. With treatment, titres
typically return to negative. Treponemal tests (e.g.,
TPHA, MHA-TP) detect T pallidum antibody, and are
reported as either positive or negative. Because these
tests typically remain positive even after treatment, a
positive treponemal test could indicate either recent
active or old (or previously treated) infection. Currently
available, rapid point-of-care tests (e.g., ICS strip) are
treponemal tests.
Effects of syphilis on pregnancy outcome
The risk of syphilis to the foetus is dependent upon the
stage of maternal infection and on the stage of preg-
nancy at which the foetus is exposed. Primary, second-
ary, early latent, and in some cases late latent, stage
maternal syphilis infection can lead to haematogenous
spread to the foetus, resulting in a systemic inflamma-
tory response [8]. Although spirochetes can cross the
placenta to the foetus from early pregnancy [9], foetal
immune systems are not mature enough to mount a
consistent immune response until about 18 to 22 weeks
gestation. After this time the characteristic features of
congenital syphilis may be seen. In addition, placental
infiltration with reduced blood flow to the foetus can
lead to growth restriction which, if severe, may result in
foetal death [8]. Foetal involvement occurs most consis-
tently in pregnant women with ‘active’ infections (i.e.
RPR titre >1:4), that is inadequately or not treated infec-
tions acquired in the five years preceding the pregnancy.
This review therefore focuses on this group of pregnant
women with active infection. Based on the available
data, an expert panel has estimated , that in the absence
of effective treatment, 25% of pregnancies to such
women will result in a 2
nd trimester miscarriage or still-
birth, 11% of pregnancies in a neonatal death at term,
13% in a preterm or low birth weight infant and an
additional 20% with clinical signs of congenital syphilis
that are attributable to syphilis. Hence, of the 75% of
the pregnancies resulting in a liveborn infant, 15%
would be expected to result in a neonatal death at term
and 17% in a preterm or low birth weight infant, with a
further 27% of babies who survive to 28 days developing
clinical signs of congenital syphilis [3]. Congenital syphi-
lis in the first 2 years of life may present with hepato-
splenomegaly, anaemia, jaundice, rash, snuffles and
pseudo-paralysis [10]. Later manifestations of congenital
syphilis, after the first 2 years of life may be an impor-
tant treatable cause of neurological, developmental, and
musculoskeletal problems and death in infants and chil-
dren in low-income settings [11]. In view of the ongoing
morbidity and mortality associated with congenital
syphilis, and because of the challenges of making a spe-
cific diagnosis, both CDC and WHO now recommend a
10 day course of intravenous or intramuscular penicillin
treatment for all infants born to mothers with untreated
or inadequately treated syphilis in pregnancy , regardless
of symptoms or clinical findings [12,13].
Treatment
Parenteral penicillin was identified as effective in the
treatment of syphilis shortly after its introduction in
1943, and is still the recommended drug for treatment
of syphilis, whether acquired sexually or through trans-
mission from mother to child during pregnancy [14].
Studies have established that penicillin is treponemoci-
dal at fairly low serum concentrations (>0.1 mug/ml),
and that longer duration regimens are more effective
than shorter duration regimens, even those achieving
higher concentrations [15]. These provide the therapeu-
tic rationale for use of relatively low doses of longer act-
ing penicillin G formulations (e.g. 2.4 million units
benzathine penicillin). Current CDC and WHO guide-
lines recommend a single dose of long acting penicillin
to treat early syphilis, and three injections of benzathine
penicillin at weekly intervals for infections of > 1 year
(or unknown) duration for infected adults, including
pregnant women [14]. For women with infection of > 1
year duration (i.e. latent infection), clinical studies sug-
gest that a single penicillin dose effectively treats the
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doses treat the mother. Other antibiotics, such as oral
tetracyclines and macrolides (e.g., erythromycin, azithro-
mycin) have been used to treat syphilis in adults, but
are not recommended either due to their toxicity in the
foetus (tetracyclines) or because they do not cross the
placental barrier (macrolides) and thus do not treat foe-
tal infection at all. Macrolide antibiotics have also been
associated with development of resistance [15,18]. Par-
enteral ceftriaxone has been used to treat syphilis in
penicillin-allergic patients, but as no controlled studies
among pregnant women have assessed its efficacy in
treating the foetus, this is not recommended in preg-
nancy [13,14].
Many factors limit the quality of evidence available
concerning the magnitude of the effects of penicillin
treatment on foetal and neonatal mortality. Syphilis in
pregnancy is a dynamic disease; the timing of infection,
re-infection and treatment can all vary, and there are a
variety of possible non-specific outcomes (including
stillbirth, preterm birth and neonatal and infant death)
that are associated with many different, and potentially
confounding factors (e.g. other infections, maternal well-
being and adherence to recommendations). Given the
longstanding recommendations regarding identification
and treatment of maternal syphilis randomised con-
trolled trials of the effect of penicillin compared to no
treatment would not be ethical. Many observational stu-
dies control for potential confounders inadequately or
not at all. In summary, despite evidence and widespread
policy acceptance of the importance of identifying and
treating syphilis during pregnancy, there are limited data
regarding the magnitude of the effect such detection
and treatment has on foetal and neonatal mortality.
Objective
The objective of this paper is to provide quantitative
estimates of the effect of antenatal syphilis detection
based on serological screening in pregnancy combined
with treatment with at least 2.4 million units penicillin
(at least a single dose of benzathine penicillin or the
equivalent multiple dose schedule of shorter acting
penicillin) on syphilis related stillbirths, neonatal mor-
tality and morbidity related to maternal syphilis infec-
tion. These effect estimates are inputs to the Lives
Saved Tool (LiST) [19] and are derived according to set
rules [20].
Methods
We systematically reviewed the published literature to
identify studies of detection and treatment of syphilis in
pregnancy for the prevention of congenital syphilis mor-
tality (latest searches performed December 2009). There
are two broad causal pathways by which active syphilis
in pregnancy may lead to mortality in the foetus/ neo-
nate – through direct infection of the foetus and leading
to an overwhelming inflammatory response (leading to
sepsis, stillbirth or preterm birth) or indirectly through
reduced placental blood flow (leading to stillbirth or low
birth weight), though this is less frequent. We searched
PubMed, EMBASE, Cochrane Libraries, and all World
Health Organisation Regional Databases and included
publications in any language [20]. Snowball searching
was used whereby literature referenced in key papers
was included. Combinations of the following search
terms were used: “congenital syphilis/ syphilis”“ preg-
nancy”“ neonate/ newborn”“ mortality”“ screening”
“syphilis/ drug therapy”“ antibiotics”“ preterm”“ still-
birth/ foetal death”“ perinatal mortality”.
Inclusion/ exclusion criteria
We used the PICO approach (Population, Intervention,
Comparison, and Outcome) to identify the studies to be
included. The population of interest is pregnant women
with active syphilis and the intervention being reviewed
is serologic detection of syphilis in pregnant women and
treatment of women with active syphilis (e.g RPR>1:4)
with at least 2.4 million units penicillin given at least 28
days prior to delivery. The comparison group is preg-
nant women with active syphilis who do not receive at
least 2.4 million units at least 28 days prior to delivery.
The outcomes of interest are adverse pregnancy out-
comes including stillbirth, preterm delivery, congenital
syphilis and neonatal mortality associated with congeni-
tal syphilis (figure 1). Within this structure we consid-
ered both randomised trials and observational studies
(figure 2). For duplicate reports of trials or studies we
counted outcome data only once, although we have
included data from secondary analyses if they added
pertinent information. Possible adverse effects of penicil-
lin treatment were not addressed as part of this review.
Abstraction, analyses and summary measures
All studies meeting the criteria above were abstracted
onto a standardised abstraction form for each outcome
of interest [20]. Each study was assessed for limitations
and graded according to the CHERG adaptation of the
GRADE technique [21]. The evidence was summarised
by outcome including a qualitative assessment of study
quality and sources of bias adapted from the Cochrane
review handbook. CHERG Rules for Evidence Review
were applied to the collective evidence to provide an
estimate for reduction in stillbirth and congenital syphi-
lis related neonatal mortality.
Separate meta-analyses were planned for the effect of
penicillin on incidence of stillbirth, preterm delivery,
congenital syphilis, and neonatal mortality. Meta-ana-
lyses were conducted with STATA version 10.0
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using I
2 and the chi-squared test. When evidence of het-
erogeneity was present (p<0.10), a random effects model
was used, otherwise a fixed effect was assumed. Sum-
mary risk ratios and corresponding 95% confidence
intervals (CI) are reported.
Results
The search strategy from all listed databases and refer-
ence lists identified 3126 records (Figure 2). After initial
screening of the title or abstract we reviewed 58 papers.
Twenty five papers, all observational studies were
abstracted and included in the final database. (Addi-
tional file 1) Some studies took into account important
potential confounders such as co-infection with malaria
or anaemia, while others did not. Additionally, some
studies assessed pregnancy outcomes in women who
were uninfected with syphilis, while others did not. One
Cochrane Review (“Antibiotics for syphilis diagnosed
during pregnancy”) was retrieved, but included no stu-
dies [23].
1. Evidence for the effectiveness of detection and
treatment of active syphilis in pregnancy in reducing
stillbirths and perinatal mortality
Eight observational studies reported the incidence of
stillbirths in treated, infected women compared with
untreated infected women. None of the studies made
any attempt to control this comparison for systematic
differences between treated and untreated women (con-
founding). Women not attending antenatal clinics or
not adhering to complex penicillin treatment regimes
may differ in their risk profiles for stillbirth, preterm
delivery and neonatal death from fully compliant
infected women.
Two early, observational studies from the United
States report very large reductions in stillbirths to preg-
nant women identified as ‘syphilitic’ by physical exami-
nation and serological testing and treated with at least
2.4 million units of penicillin G compared to untreated
syphilis positive women diagnosed at delivery (RRs of
0.15 (95%c.i. 0.10 – 0.25) and 0.06 (95%c.i. 0.01 – 0.27))
[24,25]. Four further studies reported RRs of 0.65 (95%
c.i 0.29 – 1.45)[26], 0.17 (0.02 – 1.25) [27] , 0.19 (95% c.
i. 0.10 – 0.38)[28] and 0.53 (95%c.i. 0.03 – 9.68)[29] for
stillbirth. One study reported no stillbirths in a group of
111 adequately treated RPR-positive women compared
to 5 stillbirths in 45 untreated pregnancies RR=0.04
(95%c.i. 0.00 – 0.66) [30]. Two Tanzanian cohorts paired
in setting and time [17,31] found three stillbirths
amongst 133 women with high titre syphilis who
received treatment [17], compared to 18 stillbirths
amongst 73 women with high titre syphilis who were
untreated[31] RR 0.09 (95% c.i. 0.03 – 0.30).
There is some evidence of heterogeneity across these 8
studies (P=0.02; I
2=56.8%). A random-effects meta-analysis
of all eight studies produced an estimated RR of 0.18 (95%
c.i. 0.10 - 0.33) (figure 3). The heterogeneity observed
appears to be largely attributable to a large South African
study [26]. Excluding this study from the analysis there is
no longer strong evidence of heterogeneity (P=0.65
I
2=0%). The summary risk ratio is little changed (RR 0.15:
95% c.i. 0.10 – 0.21 ). The outlying study was relatively
large, with a very low number of stillbirths in the
untreated group. This may be partly due to some women
being recruited in antenatal clinic in the 3
rd trimester, and
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Figure 1 The natural history of untreated syphilis in pregnancy.
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these studies controlled for confounding, other factors
may have contributed to the observed differences between
treated and untreated women.
Five studies compared stillbirth rates in uninfected
women compared to infected women who were treated
during pregnancy. In three of the studies the observed
stillbirth rate were slightly higher among infected
women receiving treatment than among uninfected
women (RR 1.3; 95% c.i. 0.81 – 2,13[25]: RR 1.4; 95%
c.i. 0.34 – 5.75[24]: RR 1.4; 95% c.i. 1.05 – 1.86 [32])
while two studies found no elevated stillbirth risk (RR
0.94: 95% c.i. 0.90 – 0.98 [27]: RR 0.68; 95% c.i. 0.2 –
2.4 [17]).
*some studies report on more than one outcome.  
Figure 2 Synthesis of study identification in the review of the effect of at least 2.4MU penicillin on syphilis related adverse pregnancy
outcomes.
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and penicillin treatment on perinatal mortality (i.e. still-
births and live born infants who died in the first week of
life) without distinguishing stillbirths from early neonatal
deaths. Two of these studies attempted to control con-
founding. In one cohort of 158 women with syphilis diag-
nosed at first ANC visit in rural South Africa, 5/26
untreated pregnancies with known outcomes resulted in
perinatal death, compared to 10/116 with at least 2.4 MU
penicillin (adjusted RR=0.45: 95%c.i. 0.17 – 1.12) [33].
Another South African study reported a reduction in peri-
natal mortality of 35% with each dose of penicillin received
(adjusted RR = 0.65: 95% c.i. 0.5 – 0.85) [26]. These results
are broadly consistent with the two further observational
studies that did not control for confounding. A study from
South Africa reported a RR of 0.34 (0.11 – 1 . 0 3 )[ 3 4 ]w h i l e
a study from Swaziland observed 7/24 perinatal deaths in
untreated pregnant women, 0/8 in treated women and 4/
145 in those negative for syphilis [35].
2. Evidence for the effectiveness of detection and
treatment of active syphilis in pregnancy in reducing
neonatal mortality
Two early studies from the United States, report very
large reductions in all-cause neonatal mortality in
infants of pregnant women with syphilis (RR = 0.14,
95%c.i. 0.07 – 0.27 and RR = 0.18 95%c.i. 0.03 – 0.95)
with the use of penicillin therapy [24,25]. The dosing
schedules of penicillin administered in these early stu-
dies were different to those in current use, using regular
dosing with short acting penicillin. Neither study
adjusted for potential confounding factors, but both had
an additional control group of uninfected women and
observed no excess risk of neonatal death in infected
women receiving penicillin compared with uninfected
w o m e n .T h r e em o r er e c e n to b s e r v a t i o n a ls t u d i e st h a t
also did not adjust for confounding were identified. One
study in South Africa recruited women at their first
ANC visit and compared those RPR positive women
who were treated with penicillin with those who were
not treated. To receive treatment women had to return
to get their test result. For analysis purposes, only those
completing treatment >28 days prior to delivery were
considered to have been treated. An all-cause neonatal
mortality risk ratio of 0.54 (95%c.i. 0.21 – 1.41) was
reported [26]. The treatment effect observed in this
study may have been attenuated as screening was based
on RPR test positivity without confirmatory testing and
will therefore have included some women without active
syphilis infection. This is likely to result in an underesti-
mate of the effectiveness of the invention for infected
women. The second study, in The Russian Federation,
NOTE: Weights are from random effects analysis
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Figure 3 Meta analysis of 8 observational studies showing effect of penicillin on stillbirth in pregnant women with active syphilis.
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Page 6 of 16recruited women at delivery, tested them for syphilis
using a non-treponemal test for syphilis (Wassermann
test) or a treponemal test (fluorescent treponemal anti-
body absorption) and, if positive, ascertained previous
penicillin treatment by examining their treatment cards
[36]. This study reported a risk ratio of 0.32 (95% c.i.
0.09 – 1.13) for neonatal death in those treated with
penicillin in pregnancy. The third, cross-sectional, study
from Zimbabwe used the RPR test to diagnose active
syphilis and reported a RR of 0.14 (95% c.i. 0.02 – 1.32)
for women treated with 1 dose of benzathine penicillin
at least 28 days prior to delivery compared to untreated
women [30]. A meta-analysis of these five studies results
in an estimated RR of 0.20 (95%c.i. 0.13 – 0.32).
(figure 4) There was not strong evidence of heterogene-
ity (I-squared=40.5%, p=0.15). Given the very large effect
size and the biological plausibility of a treatment effect it
is unlikely that the differences between treated and
untreated women are entirely explained by uncontrolled
confounding.
3. Evidence for the effectiveness of detection and
treatment of active syphilis in pregnancy in reducing
preterm births
Seven observational studies which did not adjust for
confounding were retrieved [24,27,29,34,37-39] and two
Tanzanian cohorts paired in time and place [17,31].
One early cohort study from the United States reported
a RR 0.18 (95% c.i. 0.03 – 0.95) for preterm birth asso-
ciated with penicillin treatment but was excluded from
further analysis as no definition of preterm birth or
how it was assessed was given [24]. The remaining
seven studies defined preterm birth as birth before 37
weeks completed gestation and used ultra-sound or last
menstrual period and clinical examination at birth to
estimate gestational age. A South African cohort
reported a RR of 0.47 (0.24 – 0.94) for preterm birth
with 1 – 3 doses of 2.4 million units penicillin G com-
pared to no treatment [34]. A second, hospital-based
cohort from Kenya which recruited mothers at delivery
reported a RR of 0.50 (95% c.i.0.26 – 0.95) for preterm
birth with penicillin treatment compared to no treat-
ment [27]. A multi-centre retrospective cohort study in
Russia reported a RR for preterm birth of 0.32 (95% c.i.
0.26 – 0.95) comparing adequately treated women to
untreated women [38]. One small South African study
observed a RR 0.08 (0.01 – 1.24) comparing treated to
untreated women [37]. In China one study found a RR
0.23 (0.1 – 0.53) for preterm birth with treatment com-
pared to untreated[39], whilst another small study
reported a RR 0.41 (0.02 – 0.72).[29] Re-analysis of the
paired Tanzanian cohorts give a RR 0.56 (95% c.i. 0.26
– 1.23). Combining these studies gives a RR of 0.36
(95% c.i. 0.27 – 0.47) for preterm birth with penicillin
treatment (figure 5). There was no evidence of hetero-
geneity p=0.49, I
2 =0.0%.
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Figure 4 Meta analysis of 5 observational studies showing effect of at least 2.4MU penicillin on all cause neonatal mortality in
pregnant women with active syphilis.
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ing in this analysis, other factors may have contributed
to the association between penicillin treatment and
reduced risk of preterm delivery. However the consis-
tency and strength of association and further analyses
o ft h eT a n z a n i ac o h o r t sp a ired in setting and time,
which adjusted for potential confounders such as
reproductive tract infections, HIV, malaria and anae-
mia, provide some evidence that the effect seen is not
entirely explained by uncontrolled confounding factors.
The Tanzania study reported the risk of preterm birth
to be 6.1 (95% c.i. 2.5 – 15.3) times higher in women
with high titre RPR positivity (i.e., active syphilis) com-
pared to uninfected women[31], while women with
high titre RPR positivity who were treated with penicil-
lin had no increased risk of preterm birth (RR =0.58;
95% c.i. 0.3 – 1.1) [17].
4. Evidence for the effectiveness of detection and
treatment of active syphilis in pregnancy in reducing the
incidence of congenital syphilis in live born infants
Three studies were identified addressing the effect of
penicillin for pregnant women with active syphilis on
the incidence of congenital syphilis. Two early cohort
studies in the United States report risk ratios of 0.05
(95% c.i. 0.01 – 0.16) and 0.05 (95% c.i. 0.03 – 0.09) for
congenital syphilis [24,25].
A large, population-based study in 6 districts in China
screened 477,656 pregnant women using Toluidine Red
Unheated Serum Test, a non-treponemal serological test
similar to RPR, for detecting current infection [40,41].
Among 2208 (0.5%) test-positive women, the risk of
congenital syphilis was 0.004 (7/1855) in those treated
with at least 2.4MU IM benzathine benzylpenicillin, and
0.23 (81/353) in those not receiving treatment (RR =
0.02 (95% c.i. 0.01 – 0.04)) [4].
These three studies showed some evidence of hetero-
geneity (p=0.08 I
2 =61.3%) although all three studies
indicate very large effects of treatment with penicillin.
This heterogeneity may be partly explained by differ-
ences in diagnosis of congenital syphilis between the
studies. A random effects meta-analysis produced an
estimated risk ratio for congenital syphilis of 0.03 (95%c.
i. 0.02 – 0.07) in those women with syphilis in preg-
nancy who were treated with penicillin, compared to
those untreated. (Figure 6)
These results are consistent with a small prospective
uncontrolled series examining 11 VDRL positive women
identified between fourteen and nineteen weeks gesta-
tion. Amniocentesis confirmed foetal infection in four
Overall  (I-squared = 0.0%, p = 0.486)
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Lu 2001
Gichangi 2004
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Zhang 2004
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RR (95% CI)
0.47 (0.24, 0.94)
0.08 (0.01, 1.24)
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100.00
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14.76
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Figure 5 Meta analysis of 7 observational studies showing effect of at least 2.4MU penicillin on preterm delivery in pregnant women
with active syphilis.
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Page 8 of 16out of 11 cases. All four mothers were treated with 2
doses of 2.4 million units Penicillin G 1 week apart. No
infant had serological evidence of congenital infection
[9]. Another larger case series of penicillin-treated
antenatal attendees with active syphilis reported that
98.2% (95% c.i 96.2 – 99.3%) of pregnancies resulted in
an uninfected infant [42]. Timing of treatment is very
important in subsequent risk of congenital syphilis. In a
large prospective cohort study in China, women com-
mencing treatment before 20 weeks gestation had a
lower rate of congenital syphilis RR=0.50 (95%c.i. 0.38 –
0.64) [43] than women treated after 20 weeks.
Quality of the evidence for estimation of the effect of at
least 2.4MU penicillin treatment in pregnant women with
active syphilis
The CHERG Rules for Evidence Review were applied
[20] (table 1)
1. Evidence of effect on perinatal deaths and stillbirths
Combining data from eight cohort studies that did not
control for potential confounding results in an estimate
for the reduction in stillbirth amongst women with
active syphilis in pregnancy of 82% (95% c.i. 67 – 90%)
with penicillin treatment (figure 3). There is a very
large, biologically plausible and consistent effect size.
S i n c en o n eo ft h e s es t u d i e sa d e q u a t e l yc o n t r o l l e df o r
potential confounding factors, other factors may have
contributed to this apparent relationship, although the
strength and the consistency of the association makes it
rather unlikely that that the association can be entirely
explained by confounding factors. Also, several studies
included a comparison group of uninfected women and
noted similar stillbirth rates in this group to the rates in
syphilis-infected women who were treated, providing
further evidence that the observed reductions in still-
births were due to treatment of syphilis. However, with-
out adjustment for confounding factors the quality of
evidence is considered low.
Four studies which examined perinatal mortality were
all consistent with a substantial reduction with penicillin
treatment.
2. Cause-specific evidence of effect on congenital syphilis
on deaths in the neonatal period
There is no high or moderate quality direct evidence for
the effect of treating women with syphilis in pregnancy
on reduction of congenital syphilis specific-neonatal
deaths. In five observational studies, treatment was con-
sistently associated with a reduction all-cause neonatal
mortality of 80% (95% c.i. 68 – 87%) (figure 4). Some
studies included a comparison group of uninfected
women and noted that neonatal mortality in syphilis-
infected women who were treated was similar. This
NOTE: Weights are from random effects analysis
Overall  (I-squared = 61.3%, p = 0.075)
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Figure 6 Meta analysis showing moderate evidence of the effect of at least 2.4MU penicillin treatment on incidence of congenital
syphilis in pregnant women with active syphilis.
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Page 9 of 16Table 1 Quality assessment of evidence for treatment with at least 2.4MU penicillin for women with active syphilis in pregnancy to prevent adverse
pregnancy and neonatal outcomes
Quality Assessment Summary of Findings
Directness Treated women
with active syphilis
Untreated women
with active syphilis
No of
studies
(ref)
Intervention Design Limitations Consistency Generalizability
to population
of interest
Generalizability
to intervention
of interest
GRADE
of
evidence
Number
events
Number
of births
Number
events
Number
of births
Effect
size
(95%
CI)
Stillbirths:
8 At least
2.4MU
penicillin
Observational
studies
no or insufficient controlling for
important potential confounding
variables
Consistent Yes Yes Low 70 2578 185 1353 RR=
0.18*
(0.10 -
0.33)
PerinatalMortality (stillbirth and early neonatal mortality):
2 At least
2.4MU
penicillin
Cohort
studies
Both from South Africa Consistent Both from South
Africa
Yes Low 39 952 19 233 RR= 0.49
- 0.65
Neonatal Mortality (All Cause):
5 At least
2.4MU
penicillin
Observational
studies
no or insufficient controlling for
important potential confounding
variables
Consistent Yes Yes Low 29 2068 62 972 RR=0.20*
(0.13 -
0.32)
Preterm birth:
7 At least
2.4MU
penicillin
Observational
studies
no or insufficient controlling for
important potential confounding
variables
Consistent Yes Yes Low 85 947 250 1012 RR=0.36*
(0.27 -
0.47)
Congenital syphilis:
3 At least
2.4MU
penicillin
Observational
studies
no or insufficient controlling for
important potential confounding
variables but as very specific
outcome unlikely to be confounded
Consistent Yes Yes Moderate 20 2745 139 715 RR=0.03*
(0.02 -
0.07)
*Based on calculated pooled estimate.
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6provides some circumstantial evidence that the observed
reductions in neonatal mortality may have been due to
treatment of syphilis. None of the studies controlled for
possible confounding factors and hence the quality of
the evidence is low.
3. Cause-specific evidence of effect on preterm birth
Seven observational cohort studies which did not con-
trol for potential confounders in this analysis consis-
tently reported reductions in preterm births with
penicillin of 64% (95% c.i. 53 – 73%) (figure 5). The
overall quality of evidence is low and distal to the mor-
tality effect. Some studies included a comparison group
of uninfected women with birth outcomes similar to
infected women treated with penicillin. This provides
some supportive evidence that the observed reductions
in preterm birth may have been due to treatment of
syphilis. The quality of the evidence is low.
4. Evidence of effect on incidence of congenital syphilis
Combining data from 3 observational studies results in
an estimated reduction in the incidence of clinical con-
genital syphilis of 97% (95% c.i. 93 – 98%) with penicil-
lin (figure 6). There is a very large, biologically plausible
and broadly consistent effect size which, given the very
specific outcome, is unlikely to be confounded by other
factors, so GRADE rules result in upgrading the quality
of evidence from low to moderate.
Estimation of effect on neonatal mortality
A recent expert consensus panel reviewing published
data has estimated that approximately 15% of livebirths
in women with active syphilis in pregnancy result in a
neonatal death from congenital syphilis and that a
further 27% have clinical evidence of syphilis in the first
year of life [3]. Current practice, based on both the
WHO and CDC guidelines for the management of pre-
sumptive congenital syphilis, includes parenteral penicil-
lin treatment for all infants born to untreated or
inadequately treated mothers[12,13]. Whilst this will
markedly reduce the incidence and later morbidity and
mortality of congenital syphilis it is likely to have less
impact on neonatal mortality as most of the neonatal
deaths from congenital syphilis occur on the first day of
life [44,45].
In a high prevalence setting in Malawi in 1990, with a
“very high” neonatal mortality NMR typology of 47/
1000, about 30% (14 per 1000) of all neonatal deaths
would be expected to be due to sepsis [46]. With a pre-
valence of active syphilis of 3.6%, without treatment in
pregnancy, for every 1000 pregnant women 36 women
would be infected with active syphilis of whom 9 (25%)
would be expected to have a stillbirth and 27 a livebirth.
Overall 4 women (11% of pregnancies, 15% of livebirths)
would expect to result in a term neonatal death attribu-
table to syphilis i.e. a “sepsis” death. Assuming 97% effi-
cacy about 8% (3.88/47) of overall neonatal deaths and
28% (3.88/14) of neonatal sepsis deaths in women with
syphilis could be averted.
This is likely to be a conservative estimate. Additional
neonatal deaths attributable to maternal syphilis are
expected due to the effect of syphilis in pregnancy on
preterm delivery and low birth weight, with their asso-
ciated increased neonatal mortality. Four recent studies
report 17% (90/536) of live births in women with syphi-
lis in pregnancy were preterm [27,31,47,48]. Preterm
delivery was reported six times more frequently in RPR
positive women compared with RPR negative women
[31].
Discussion
Mortality from untreated maternal syphilis remains an
important yet preventable cause of neonatal deaths and
stillbirths. The systematic review identified five relevant
studies, suggesting a large and consistent effect size on
all-cause neonatal mortality for women with untreated
syphilis in pregnancy but none controlled for confound-
ing. Unsurprisingly, no randomised trials have examined
the effect of penicillin or alternative treatments for
syphilis in pregnancy which would have provided high
quality direct evidence regarding the neonatal cause-spe-
c i f i cm o r t a l i t ye f f e c to fp e n icillin treatment for women
with syphilis in pregnancy. There is low quality evidence
of the effect of penicillin in reducing all cause perinatal
mortality. Based on studies of the incidence of congeni-
tal syphilis (3 studies, 159 cases,) we estimate that pre-
natal detection of maternal syphilis infection and
treatment with at least 2.4 million units of penicillin
reduces the incidence of congenital syphilis by 97%
(95% c.i 93 – 98%). Assuming conservatively that peni-
cillin treatment in pregnancy does not affect the case
fatality from congenital syphilis, the reduction in conge-
nital syphilis neonatal mortality will be equal to the
reduction in incidence i.e. 97%. Assuming 15% of live-
births in women with active syphilis in pregnancy result
in a congenital syphilis-related neonatal death at term,
treatment before the last trimester of pregnancy with at
least 2.4MU penicillin would be expected to avert 97%
of these deaths. (Table 2) The effect on neonatal mortal-
ity is likely to be underestimated as the six-fold increase
in preterm birth is not taken into account in this esti-
mate. In addition, this review has, of necessity, been
based on studies in which treatment was given at least
28 days prior to delivery. However, studies support the
belief that treatment earlier in pregnancy ideally before
24 – 28 weeks gestation has a greater effect on preg-
nancy outcome and hence we may be underestimating
the effect of earlier treatment. Thirdly this does not take
into account late foetal demise or stillbirth, the most
common pregnancy outcome caused by untreated
maternal syphilis, estimated to occur in about 25% of
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genital syphilis.
The information used on the extent to which maternal
syphilis infection affects pregnancy outcome is based on
a variety of sources. Randomised controlled trials of the
effect of penicillin compared to no treatment would not
be ethical. Studies reporting on the effect of syphilis in
pregnancy on pregnancy outcome e.g. stillbirth, neonatal
death, infected infant most commonly compare the out-
come of untreated pregnancies with treated pregnancies
or outcome of infected pregnancies versus non-affected
pregnancies. In both cases the two groups may differ
with respect to other risk factors for neonatal outcome,
potential confounders (e.g. maternal age), co-infections
(e.g. malaria and HIV) and maternal anaemia. Two
recent studies which sought to control for potential con-
founding variables, have reported on the association of
untreated active syphilis in pregnancy (RPR/VDRL titre
>= 1:4 and reactive MHA-TP assay) with peri- and neo-
natal outcomes in low income settings. A study from
Malawi, in a population with a prevalence of active
syphilis of 3.6%, reported an adjusted odds ratio (OR) of
10.89 (95% c.i 6.61 – 17.93) for stillbirth and 4.86 (95%
c.i. 2.73 – 10.36) for neonatal death [49]. An estimated
11% (95% c.i. 6 – 17%) of neonatal deaths and 26% (95%
c.i.18 – 35%) of stillbirths in this population were attri-
butable to syphilis. A cohort study in Tanzania in which
7.7% of women tested seropositive for syphilis, reported
adjusted risk ratios (RR) of 18.1 (95% c.i.5.5 – 59.6) for
stillbirth, of 3.3 (95% c.i. 2.0 – 5.4) for low birth weight
(LBW), of 6.1 (95% c.i. 2.5 – 15.3) for preterm birth,
and of 2.1 (95% c.i. 1.0 – 4.2) for intra-uterine growth
retardation (IUGR) [31].
A limitation of the GRADE approach, well illustrated
in the present context, is its potential to produce results
which could be misinterpreted by the reader who
glances at the results but does not have time to read
them and the conclusions carefully. There can be no
doubt, based on our understanding of biological
mechanisms, and the consistent and large effects seen
across multiple studies, that timely diagnosis and treat-
ment with benzathine penicillin of active syphilis infec-
tion in pregnant women substantially reduces the risk of
stillbirth, and neonatal morbidity and mortality. How-
ever, all of the available quantitative evidence regarding
the precise magnitude of these reductions comes from
Table 2 Cause specific mortality effect and quality grade of the estimate for the effect of at least 2.4MU penicillin
treatment for active syphilis in pregnancy
Cause specific mortality to act on:
The proportion of stillbirth mortality that is related to syphilis.
The proportion of preterm mortality that is related to syphilis.
The proportion of neonatal sepsis mortality that is due to congenital syphilis.
Cause specific estimate of effect in affected pregnancies and range:
Reduction in stillbirth of 82% (95% c.i. 67 – 90%)
Reduction in the incidence of preterm delivery of 64% (95% c.i. 53 – 73%)
Reduction in the incidence of clinical congenital syphilis of 97% (95% c.i. 93 – 98%)
Assuming 15% of livebirths from syphilis affected pregnancies result in a neonatal death attributable to congenital syphilis (expert consensus) and
that treatment does not affect case fatality, 97% (95%c.i. 93 – 98%) of these deaths could be averted.
Quality of input evidence:
For stillbirth – There is a large and consistent effect size from 8 observational studies. The GRADE quality of evidence is low.
For preterm - There is a large and consistent effect size from 7 observational studies. The GRADE quality of evidence is low.
There is a large and consistent effect size on incidence of clinical congenital syphilis and confounding is unlikely, so GRADE rules result in upgrading
the low to moderate quality evidence.
The GRADE recommendation is STRONG, based on large and consistent effect sizes across studies, and biological plausibility.
Proximity of the data to cause specific mortality effect:
For the effect on preterm and neonatal sepsis due to congenital syphilis, the evidence is on incidence and distal to mortality estimate.
Possible adverse effects:
Penicillin allergic symptoms may occur in 2% of individuals [89]; however, severe allergic reactions (e.g. anaphylaxis) are rare events, estimated to
occur in 10 to 50 of every 100,000 exposed individuals [90,91]. Up to 40% of patients with primary or secondary syphilis may experience Jarisch-
Herxheimer reactions with antibiotic treatment. These reactions involving malaise, anxiety, fever, headache, sweating, or rigors are believed caused
by microbial lysis. If the reaction occurs late pregnancy it could lead to fetal distress, uterine contractions and preterm delivery [92,93]. There is some
evidence of possible increased maternal infection after antepartum treatment [94]
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classified as “low quality” by the GRADE process unless
one can essentially rule out any confounding (or other
threats to validity). One is very rarely in a position to do
this. The GRADE approach is, however, a two stage pro-
cess, first grading the quality of evidence and seconda-
rily the strength of recommendation. This is an
intervention which should clearly be strongly recom-
mended (GRADE recommendation STRONG) in areas
where syphilis is prevalent even though it comes with a
tag of “low quality evidence” attached. We should also
emphasise the distinction between the quality of the evi-
dence assigned by the GRADE process and the quality
of individual studies contributing to that evidence. In
many cases, well designed and executed observational
studies will produce only “low quality evidence” in
GRADE terms.
We assessed interventions that involved any treat-
ment with at least 2.4 million units of penicillin, and
did not attempt to compare longer versus shorter peni-
cillin regimens. Foetal syphilis infection is, by defini-
tion, of less than one year duration, and thus falls
under WHO and CDC treatment recommendations for
early infection of a single intramuscular dose of 2.4
million units of benzathine penicillin (although effec-
tive treatment of a mother with latent infection would
require additional doses per those recommendations).
Watson-Jones found such a single dose treatment to
be effective in preventing syphilis-associated adverse
pregnancy outcomes among Tanzanian women attend-
ing ANC and, importantly, that 229 women ≤ 28
weeks gestation who received a single dose of penicil-
lin had no increased risk for adverse pregnancy out-
come compared with seronegative women[17].
Gestational age at treatment is likely quite important,
as foetal inflammatory response to treponemal infec-
tion occurs in the latter part of the 2
nd trimester of
pregnancy. Detection and treatment of syphilis infec-
tion later than 24 to 28 weeks gestation may be too
late to prevent occurrence of some foetal losses, still-
births or preterm births. Completing 3 penicillin doses
has been observed to be highly correlated with gesta-
tional age at diagnosis, with women attending ANC
later in pregnancy less likely to receive all 3 doses [50].
While some studies have reported multiple penicillin
d o s e st ob em o r ee f f e c t i v ethan single dose regimens
in reducing adverse pregnancy outcomes associated
with maternal syphilis infection, these did not report
results by gestational age at first treatment [26,34]. It
is possible that longer regimens may confer some addi-
tional benefit in reducing adverse pregnancy outcomes,
particularly among women co-infected with HIV [51]
or in women with secondary infection [42]; however
we were not able to assess this using existing data.
Detecting and measuring accurately the incidence of
congenital syphilis is problematic even in countries with
comprehensive surveillance systems [52]. False positives
may occur with RPR/ VDRL for example with yaws,
viral infections, autoimmune conditions and pregnancy.
These tests are user-dependent and onsite testing
reduces sensitivity [47,53-55] whilst laboratory-based
screening involves women returning for the result. This
delay in initiating treatment may result in fewer women
receiving treatment or in insufficient time for treatment
to be adequately effective prior to delivery. The most
practical approach in low inco m es e t t i n g si st oe n s u r e
early screening and prompt, ideally same visit, treatment
of positives, with follow-up treatment of mothers with
additional penicillin doses if required e.g. late latent or
tertiary syphilis. In settings lacking laboratory capacity
for RPR testing this may be best achieved through use
of point-of-care treponemal tests [56]. This approach is
currently being implemented in several countries. A
recent cluster randomised trial found using point-of-
care treponemal tests and first dose of penicillin in a
one-stop clinic reduced congenital syphilis by 93.5%
(95% c.i 66.0%–98.6%) compared with off-site RPR test-
i n ga n dp e n i c i l l i nt r e a t m e n ta tn e x tA N Cv i s i t[ 5 7 ] .
However, current point-of-care tests do not distinguish
between past and present infection [58] and thus may
result in some over-treatment of positive mothers who
have been previously treated. Studies suggest that risks
to the mother and costs of unnecessary treatment are
small [14,59]; however, introduction of a dual trepone-
mal/non-treponemal point of care test, anticipated in
the near future, should help address this problem.
Whilst policies for syphilis control are present in over
three-quarters of 22 countries surveyed in Sub-Saharan
Africa, in practice many women remain unscreened and
untreated. Even amongst those receiving treatment, it is
often only received after the critical first 24 weeks of
pregnancy [60]. In a study in Tanzania, only 43% of
women attending ANC were screened and only 61% of
those positive and 37% of their partners were treated
[61]. Other studies report similar figures [47,62-68]. To
prevent syphilis related adverse pregnancy outcomes
women must access ANC sufficiently early, be tested,
receive results promptly, be treated adequately, and
remain uninfected for the rest of pregnancy [69]. Imple-
menting programmes can be difficult and even in high
income countries cases of syphilis-related stillbirth and
congenital syphilis still occur [70]. Contributing factors
include failure to attend ANC or attending only in the
third trimester, lack of testing supplies/ transport for
specimens and treatment available at the antenatal site,
not returning for results/ treatment, infection or re-
infection during pregnancy, and (rarely) failure of treat-
ment [70-72]. Resolving some of these operational issues
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cerns exist regarding sustainability [73-75].
How to screen most efficiently for syphilis is currently
the major issue for low income countries [69]. The eco-
nomic cost of screening and treating cases of syphilis in
pregnancy in Tanzania has been estimated to be $1.44 per
women screened, $20 per woman treated and $186 per
case of stillbirth or low birth weight averted [76]. Model-
ling has suggested on-site testing with ICS to be the most
effective and least costly strategy [77] and translation of
these results into effective routine programmes has been
demonstrated [59,75]. Discussion surrounds whether
screening should be carried out once or twice during preg-
nancy, though ensuring screening once for every woman
would represent a major step forward. 0.4 – 2.8% of preg-
nant women in high prevalence areas were found to have
become seropositive for syphilis between testing in the 1
st
and the 3
rd trimester [17,78-80]. Contact tracing of part-
ners to reduce the risk of re-infection is resource intensive
and rarely carried out [34]. It is unclear what proportion
of cases of congenital syphilis attributed to ‘penicillin treat-
ment failure’ are actually due to re-infection [65,80-84].
Co-infection with HIV infection compromises the ser-
ological response to and probably effectiveness of syphi-
lis treatment of syphilis in adults [51,85]. The effect of
HIV on treatment of syphilis in pregnancy is not
known. However syphilis may increase the transmission
of congenital HIV infection [86,87]. Introducing a func-
tioning programme of syphilis screening and treatment
into already established prenatal HIV testing services
m a yb eac o s t - e f f e c t i v es t r a t e g ya n da no p p o r t u n i t yf o r
cohesion to maximise prevention of mother to child
transmission of both HIV and syphilis [59,88].
Conclusion
Evidence supports that at least 2.4MU penicillin given at
least 28 days prior to delivery is effective in the treatment
of syphilis in pregnant women to prevent congenital syphi-
lis, with greatest effect when given early in pregnancy
(before 24 -28 weeks). Our estimates suggest such treat-
ment results in at least a 97% reduction in the incidence of
congenital syphilis. Assuming that penicillin treatment
does not alter case fatality from congenital syphilis, 97% of
neonatal deaths from congenital syphilis may be averted
by appropriate timely penicillin treatment for the affected
mother during pregnancy. In addition, low grade evidence
consistently supports large reductions amongst infected
women in risks of stillbirth (82%), preterm birth (64%) and
neonatal mortality (80%) with appropriate and timely
treatment but uncontrolled confounding factors may
account for part of these apparent effects.
Detection and appropriate timely penicillin treatment
is an effective intervention to reduce adverse syphilis-
related pregnancy outcomes. The strength of GRADE
recommendation is strong based on biological plausibil-
ity and consistent and large effects seen across all stu-
dies reviewed. More research is required to identify the
most cost effective strategy for achieving maximum cov-
erage of screening for all pregnant women and access to
treatment if required.
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